- Home
- QSI vs AARD Comparison
QSI vs AARD Comparison
Compare QSI & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QSI | AARD |
|---|---|---|
| Founded | 2013 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 273.7M | 281.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | QSI | AARD |
|---|---|---|
| Price | $0.93 | $6.10 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 10 |
| Target Price | $1.00 | ★ $19.63 |
| AVG Volume (30 Days) | ★ 3.0M | 325.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $196.35 | N/A |
| Revenue Next Year | $229.03 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.84 | $4.74 |
| 52 Week High | $3.10 | $17.94 |
Technical Indicators
Market Signals| Indicator | QSI | AARD |
|---|---|---|
| Relative Strength Index (RSI) | 42.06 | 26.00 |
| Support Level | N/A | N/A |
| Resistance Level | $1.03 | $15.88 |
| Average True Range (ATR) | 0.06 | 0.55 |
| MACD | 0.00 | -0.63 |
| Stochastic Oscillator | 42.13 | 16.89 |
Price Performance
Historical ComparisonAbout QSI Quantum-Si Incorporated
Quantum-Si Inc is a life sciences company focused on the development and commercialization of proteomics research tools. The company has designed and developed a hardware, consumable, and software solution to provide a solution for protein detection and analysis. It has developed a proprietary universal single-molecule detection platform that enables Next-Generation Protein Sequencing (NGPS), the ability to sequence proteins.
About AARD Aardvark Therapeutics Inc.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.